Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hunt

Showing results (661-670 of 671) with videos related to

Pageof 68
Sort By:
Bioorganic & Medicinal Chemistry Letters|April 11, 2015
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agentWeifang Shan, Aaron Balog, Claude Quesnelle, et al.
Journal of Medicinal Chemistry|March 19, 2004
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|September 3, 2015
Correction to N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor AgentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|August 23, 2002
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, S David Kimball, Raj N Misra, et al.
Journal of Medicinal Chemistry|March 6, 2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamilyGretchen M Schroeder, Yongmi An, Zhen-Wei Cai, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid TumorsAshvinikumar V Gavai, Claude Quesnelle, Derek Norris, et al.
ACS Medicinal Chemistry Letters|July 16, 2021
Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 InhibitorsEmily C Cherney, Liping Zhang, Weiwei Guo, et al.
Journal of Medicinal Chemistry|September 20, 2021
Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug DesignAshvinikumar V Gavai, Derek Norris, George Delucca, et al.
Msphere|June 15, 2022
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay HarmonizationAmy B Karger, James D Brien, Jayne M Christen, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay HarmonizationAmy B Karger, James D Brien, Jayne M Christen, et al.
Pageof 68

Showing results (661-670 of 671) with videos related to

Sort By:
Pageof 68
Bioorganic & Medicinal Chemistry Letters|April 11, 2015
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agentWeifang Shan, Aaron Balog, Claude Quesnelle, et al.
Journal of Medicinal Chemistry|March 19, 2004
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|September 3, 2015
Correction to N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor AgentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|August 23, 2002
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, S David Kimball, Raj N Misra, et al.
Journal of Medicinal Chemistry|March 6, 2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamilyGretchen M Schroeder, Yongmi An, Zhen-Wei Cai, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid TumorsAshvinikumar V Gavai, Claude Quesnelle, Derek Norris, et al.
ACS Medicinal Chemistry Letters|July 16, 2021
Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 InhibitorsEmily C Cherney, Liping Zhang, Weiwei Guo, et al.
Journal of Medicinal Chemistry|September 20, 2021
Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug DesignAshvinikumar V Gavai, Derek Norris, George Delucca, et al.
Msphere|June 15, 2022
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay HarmonizationAmy B Karger, James D Brien, Jayne M Christen, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay HarmonizationAmy B Karger, James D Brien, Jayne M Christen, et al.
Pageof 68